Your browser doesn't support javascript.
India's pragmatic vaccination strategy against COVID-19: a mathematical modelling-based analysis.
Mandal, Sandip; Arinaminpathy, Nimalan; Bhargava, Balram; Panda, Samiran.
  • Mandal S; Division of Epidemiology and Communicable Diseases (Clinical Studies, Projection & Policy Unit), Indian Council of Medical Research, New Delhi, India.
  • Arinaminpathy N; MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.
  • Bhargava B; Indian Council of Medical Research, New Delhi, India.
  • Panda S; Division of Epidemiology and Communicable Diseases (Clinical Studies, Projection & Policy Unit), Indian Council of Medical Research, New Delhi, India pandasamiran@gmail.com.
BMJ Open ; 11(7): e048874, 2021 07 02.
Article in English | MEDLINE | ID: covidwho-1295215
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT

OBJECTIVES:

To investigate the impact of targeted vaccination strategies on morbidity and mortality due to COVID-19, as well as on the incidence of SARS-CoV-2, in India.

DESIGN:

Mathematical modelling. SETTINGS Indian epidemic of COVID-19 and vulnerable population. DATA SOURCES Country-specific and age-segregated pattern of social contact, case fatality rate and demographic data obtained from peer-reviewed literature and public domain. MODEL An age-structured dynamical model describing SARS-CoV-2 transmission in India incorporating uncertainty in natural history parameters was constructed.

INTERVENTIONS:

Comparison of different vaccine strategies by targeting priority groups such as keyworkers including healthcare professionals, individuals with comorbidities (24-60 years old) and all above 60. MAIN OUTCOME

MEASURES:

Incidence reduction and averted deaths in different scenarios, assuming that the current restrictions are fully lifted as vaccination is implemented.

RESULTS:

The priority groups together account for about 18% of India's population. An infection-preventing vaccine with 60% efficacy covering all these groups would reduce peak symptomatic incidence by 20.6% (95% uncertainty intervals (UI) 16.7-25.4) and cumulative mortality by 29.7% (95% CrI 25.8-33.8). A similar vaccine with ability to prevent symptoms (but not infection) will reduce peak incidence of symptomatic cases by 10.4% (95% CrI 8.4-13.0) and cumulative mortality by 32.9% (95% CrI 28.6-37.3). In the event of insufficient vaccine supply to cover all priority groups, model projections suggest that after keyworkers, vaccine strategy should prioritise all who are >60 and subsequently individuals with comorbidities. In settings with weakest transmission, such as sparsely populated rural areas, those with comorbidities should be prioritised after keyworkers.

CONCLUSIONS:

An appropriately targeted vaccination strategy would witness substantial mitigation of impact of COVID-19 in a country like India with wide heterogeneity. 'Smart vaccination', based on public health considerations, rather than mass vaccination, appears prudent.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2021-048874

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans / Middle aged / Young adult Country/Region as subject: Asia Language: English Journal: BMJ Open Year: 2021 Document Type: Article Affiliation country: Bmjopen-2021-048874